-
Something wrong with this record ?
Statin Intolerance: the Clinician's Perspective
T. Stulc, R. Ceška, AM. Gotto,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
NT12217
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Medline Complete (EBSCOhost)
from 1999-07-01 to 1 year ago
- MeSH
- Hyperlipidemias drug therapy MeSH
- Cardiovascular Diseases drug therapy MeSH
- Humans MeSH
- Myalgia chemically induced MeSH
- Risk Factors MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage adverse effects therapeutic use MeSH
- Drug Tolerance MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. However, most patients who experience adverse symptoms during statin use are able to tolerate at least some degree of statin therapy. Given the profound cardiovascular benefits derived from statins, an adequate practical approach to statin intolerance is, therefore, of great clinical importance. Statin intolerance can be defined as the occurrence of myalgia or other adverse symptoms that are attributed to statin therapy and that lead to its discontinuation. In reality, these symptoms are actually unrelated to statin use in many patients, especially in those with atypical presentations following long periods of treatment. Thus, the first step in approaching patients with adverse symptoms during the course of statin therapy is identification of those patients for whom true statin intolerance is unlikely, since most of these patients would probably be capable of tolerating adequate statin therapy. In patients with statin intolerance, an altered dosing regimen of very low doses of statins should be attempted and, if tolerated, should gradually be increased to achieve the highest tolerable doses. In addition, other lipid-lowering drugs may be needed, either in combination with statins, or alone, if statins are not tolerated at all. Stringent control of other risk factors can aid in reducing cardiovascular risk if attaining lipid treatment goals proves difficult.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020205
- 003
- CZ-PrNML
- 005
- 20190821135603.0
- 007
- ta
- 008
- 160722s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11883-015-0552-3 $2 doi
- 024 7_
- $a 10.1007/s11883-015-0552-3 $2 doi
- 035 __
- $a (PubMed)26490078
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Štulc, Tomáš, $u 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, U Nemocnice 1, CZ 128 21, Praha 2 / Prague, Czech Republic. TSTULC@LF1.CUNI.CZ. $d 1965- $7 xx0056711
- 245 10
- $a Statin Intolerance: the Clinician's Perspective / $c T. Stulc, R. Ceška, AM. Gotto,
- 520 9_
- $a Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. However, most patients who experience adverse symptoms during statin use are able to tolerate at least some degree of statin therapy. Given the profound cardiovascular benefits derived from statins, an adequate practical approach to statin intolerance is, therefore, of great clinical importance. Statin intolerance can be defined as the occurrence of myalgia or other adverse symptoms that are attributed to statin therapy and that lead to its discontinuation. In reality, these symptoms are actually unrelated to statin use in many patients, especially in those with atypical presentations following long periods of treatment. Thus, the first step in approaching patients with adverse symptoms during the course of statin therapy is identification of those patients for whom true statin intolerance is unlikely, since most of these patients would probably be capable of tolerating adequate statin therapy. In patients with statin intolerance, an altered dosing regimen of very low doses of statins should be attempted and, if tolerated, should gradually be increased to achieve the highest tolerable doses. In addition, other lipid-lowering drugs may be needed, either in combination with statins, or alone, if statins are not tolerated at all. Stringent control of other risk factors can aid in reducing cardiovascular risk if attaining lipid treatment goals proves difficult.
- 650 _2
- $a kardiovaskulární nemoci $x farmakoterapie $7 D002318
- 650 _2
- $a tolerance léku $7 D004361
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a statiny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D019161
- 650 _2
- $a hyperlipidemie $x farmakoterapie $7 D006949
- 650 _2
- $a myalgie $x chemicky indukované $7 D063806
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Češka, Richard, $u 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, U Nemocnice 1, CZ 128 21, Praha 2 / Prague, Czech Republic. $d 1957- $7 nlk19990074195
- 700 1_
- $a Gotto, Antonio M $u Weill Cornell Medical College, New York, 1305 York Avenue, Y-807, New York, NY, 10021, USA.
- 773 0_
- $w MED00186151 $t Current atherosclerosis reports $x 1534-6242 $g Roč. 17, č. 12 (2015), s. 69
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26490078 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20190821135840 $b ABA008
- 999 __
- $a ok $b bmc $g 1154875 $s 944733
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 17 $c 12 $d 69 $i 1534-6242 $m Current atherosclerosis reports $n Curr Atheroscler Rep $x MED00186151
- GRA __
- $a NT12217 $p MZ0
- LZP __
- $a Pubmed-20160722